Your session is about to expire
← Back to Search
Ponatinib for Cancer
Study Summary
This trial looks at the effectiveness of ponatinib hydrochloride for treating metastatic cancer that has failed previous treatment and has DNA sequence alterations.
- Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what medical conditions is ponatinib hydrochloride typically prescribed?
"Ponatinib hydrochloride may be a useful treatment for renal dysfunction, leukemia, myeloid issues, accelerated phase ailments and chronic kidney disease."
Has the FDA sanctioned ponatinib hydrochloride?
"Ponatinib hydrochloride has been rated a 2 for safety due to existing clinical evidence affirming its security, yet no data is available that can confirm the drug's efficacy."
Is this experiment still open to new participants?
"To the contrary, clinicaltrials.gov indicates that this trial is not currently admitting participants; although initially published on February 24th 2015 and most recently updated on September 14th 2023, it does not appear to be in search of fresh patients presently. 2534 other trials are recruiting now though."
Is this the premiere clinical trial in its field?
"Since 2007, ponatinib hydrochloride has been the subject of several medical investigations. The first trial was conducted in 2007 under Baxter Healthcare Corporations' sponsorship and involved 4640 patients. After that initial study, it received its Phase 4 drug approval before later being trialed across 1214 cities within 39 countries with 69 active trials ongoing."
To what capacity is enrollment for this clinical trial currently open?
"This research protocol is no longer recruiting participants. Initially posted on February 24th 2015 and last revised in September 14th 2023; for those interested in alternative studies, there are presently 2465 trials with cancer-related objectives and 69 investigations involving ponatinib hydrochloride that are actively seeking patients."
Share this study with friends
Copy Link
Messenger